![Milbank LLP [Suhrud Mehta]](https://www.milbank.com/a/web/euTXYYe9CYbrWe86ryopLD/8ADADw/mehta-suhrud-lon-web.jpg "Milbank LLP [Suhrud Mehta]")
![Milbank LLP [Andrew Lowndes]](https://www.milbank.com/a/web/vBi3UJro7kjRFoHCvrJuZS/9CodiE/lowndes-andrew-lon-web.jpg "Milbank LLP [Andrew Lowndes]")
Milbank LLP advised the arrangers in connection with $1.9 billion (equivalent) syndicated term loan B and revolving credit facilities made available to Dechra Pharmaceuticals. The proceeds from the financing were used to refinance Dechra’s existing unitranche facilities.
Dechra Pharmaceuticals was acquired by a consortium led by EQT in 2024 and is a global specialist in veterinary pharmaceuticals and related products business, whose expertise is in the development, manufacture, marketing and sales of high-quality products exclusively for veterinarians worldwide.
The Milbank team was led by Global Leveraged Finance/Capital Markets partner Suhrud Mehta, special counsel Andrew Lowndes, associate James Aurelius and trainee solicitor Archie Hunt. The team also included New York Global Leveraged Finance partner Spencer Pepper and associate Mitch Cooper, New York Tax partner Eschi Rahimi-Laridjani and associate Wenyi Hua, and London Tax partner Alan Rafferty and associate Jade Du Berry.
